(NASDAQ: XENE) Xenon Pharmaceuticals's forecast annual revenue growth rate of 235.72% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.26%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.29%.
Xenon Pharmaceuticals's revenue in 2026 is $7,500,000.On average, 21 Wall Street analysts forecast XENE's revenue for 2026 to be $345,323,002, with the lowest XENE revenue forecast at $0, and the highest XENE revenue forecast at $2,183,745,795. On average, 21 Wall Street analysts forecast XENE's revenue for 2027 to be $8,758,276,468, with the lowest XENE revenue forecast at $1,141,787,087, and the highest XENE revenue forecast at $36,731,020,223.
In 2028, XENE is forecast to generate $25,298,175,096 in revenue, with the lowest revenue forecast at $10,248,215,028 and the highest revenue forecast at $73,897,957,703.